The Site Built for Difficult Molecules
Not every pharmaceutical development programme involves a straightforward API in a standard formulation. Some molecules are highly cytotoxic. Some are scheduled narcotics. Some are biologically active at doses measured in micrograms. These are not unusual compounds at the edges of drug development. They are increasingly common in oncology, neurology, and rare disease pipelines.
Ardena’s Pamplona facility, which operates under the Idifarma brand within the Ardena network, is the site in the group best equipped to handle them. OEB 4 and 5 containment, controlled substance manufacturing licences, and a formulation team experienced in the specific challenges of high-potency and low-solubility molecules make Pamplona the natural home for programmes that other sites cannot take on.
HPAPI Manufacturing and Containment
Pamplona’s HPAPI infrastructure includes containment isolators for handling at OEB 4 and 5, dedicated manufacturing suites with independent HVAC systems, and validated decontamination procedures using hydrogen peroxide vapour. The site’s environmental monitoring programme covers HPAPI air monitoring in work areas using validated analytical methods capable of detecting compounds at the nanogram per cubic metre level.
The containment capability supports both drug substance handling (weighing, dispensing, and transfer of HPAPI starting materials and intermediates) and drug product manufacture (blending, granulation, and tabletting of HPAPI oral solid drug products). Yield accountability and mass balance documentation are maintained throughout, meeting the strict record-keeping requirements associated with potent compound manufacturing.
Controlled Substance Manufacturing
Pamplona holds manufacturing authorisations for narcotic and psychotropic substances under Spanish and European regulatory requirements. This enables the site to manufacture clinical batches of scheduled compounds including opioids, cannabinoids, and emerging psychedelic-derived therapeutics within a GMP framework that meets both EU GMP and the specific national requirements of the Spanish competent authority (AEMPS).
The site has experience managing the import and export licence requirements associated with controlled substance clinical supply, and can coordinate with regulatory authorities in importing countries to ensure that cross-border shipments are compliant.
Oral Solid Formulation for Challenging Molecules
Pamplona’s formulation team specialises in molecules that present both potency and solubility challenges simultaneously. The site operates hot melt extrusion and wet milling capability for bioavailability enhancement, alongside standard granulation and tabletting for more conventional formulations. High-sensitivity LC-MS/MS analytical methods are used for content uniformity and dissolution testing of HPAPI drug products where standard HPLC-UV methods lack sufficient sensitivity.
What Pamplona Is Best Suited For
| Programme Type | Why Pamplona Is a Good Fit |
| Oncology HPAPI oral solid | OEB 4-5 containment; formulation development; GMP clinical batch; high-sensitivity analytical methods |
| ADC payload synthesis or handling | HPAPI containment for cytotoxic warheads; controlled transfer to conjugation chemistry steps |
| Controlled substance development | AEMPS manufacturing licence; experience with import/export documentation; GMP batch supply for scheduled compounds |
| Psychedelic-assisted therapy programmes | Schedule 1 and 2 handling capability; experience with regulatory requirements for novel controlled substance clinical programmes |
| BCS Class II HPAPI formulation | HME and wet milling with containment; simultaneous management of solubility challenge and exposure risk |
| Low-dose solid dosage forms | Experience with microgram-level content uniformity; validated LC-MS/MS release methods |
Integration with the Ardena Network
For ADC programmes, Pamplona’s HPAPI capabilities connect with the formulation and fill-finish work at Ghent and the bioanalytical programme at Assen. For programmes involving solid state uncertainty, Pamplona’s formulation work draws on the solid state research expertise at Ghent. For programmes requiring simultaneous EU and US GMP compliance, Pamplona’s EU GMP certification and the US cGMP status of the Somerset facility together provide the geographic footprint needed for dual submissions.
